Tarsus Pharmaceuticals, Inc.

1. 01

   Behind SPY and its sector fund XLV over 1 year

   1 month: −6.8% (SPY −1.6%, XLV +13.5%). 3 months: +12.7% (SPY −0.4%, XLV +15.5%). 1 year: −3.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: TARS, SPY and XLV · as of 4 Nov 2026

2. 02

   5.7 days to cover short interest

   5.7M shares were sold short at the 15 Oct 2026 settlement, 11.6% of the 49.3M shares outstanding; covering them would take 5.7 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

3. 03

   Volume 2.8× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 2.6M shares was 2.8× the average of the 30 sessions before it (911.3K), as the price fell 4.9%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

4. 04

   Below its 50-day average, above its 200-day

   The 4 Nov 2026 close of $69.07 was 8.1% below its 50-day average ($75.12) and 1.9% above its 200-day average ($67.78). It has closed above the 200-day for 13 sessions, since 19 Oct 2026. The 50-day average crossed above the 200-day on 21 Sep 2026, 32 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

5. 05

   40% of the way up its 52-week range

   Closed at $69.07 on 4 Nov 2026: 24.5% below the 52-week high of $91.53 (4 Sep 2026) and 28.2% above the low of $53.89 (15 Jul 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

At the 4 Nov 2026 close